RxDoctor Payments Data

Lynda Dunlop

Psychiatric/Mental Health · Bloomfield, CTNPI 1013312206

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.7% of the total across 341 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.2% — the pattern of someone who eats at a lot of different presentations. Among psychiatric/mental health clinicians in CT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,785in general payments, 2019–2025

Across 341 payments — averaging $22.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Otsuka America Pharmaceutical, Inc.$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$900
  • Sunovion Pharmaceuticals Inc.$710
  • Lundbeck LLC$699
  • Axsome Therapeutics, Inc.$621
  • plus $2K from 10 others

What the payments were for

  • Food & beverage$7,68799%
  • Education$981%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,785 in reported general payments places this provider in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

See all psychiatric/mental health providers in Connecticut

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl29$58,148
RexultiBrexpiprazole15$23,178
AzstarysSerdexmethylphen/Dexmethylphen11$4,636
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine37$1,888
Gabapentin43$1,402
Mirtazapine30$1,205
Venlafaxine Hcl ErVenlafaxine Hcl36$759
Buspirone Hcl37$638
Clonazepam50$595
Lamotrigine13$591
Quetiapine Fumarate27$582
Bupropion XlBupropion Hcl17$452
Quetiapine Fumarate ErQuetiapine Fumarate13$413
Aripiprazole13$399
Paroxetine Hcl14$286

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$1,575$58,14829 claims
Otsuka America Pharmaceutical, Inc.Rexulti$1,546$23,17815 claims
Corium, LLCAzstarys$64$4,63611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 679 psychiatric/mental health providers in Connecticut.

Other psychiatric/mental health in Bloomfield

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →